California State Teachers Retirement System lowered its holdings in Catalent Inc (NYSE:CTLT) by 9.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 201,485 shares of the company’s stock after selling 21,449 shares during the period. California State Teachers Retirement System owned approximately 0.15% of Catalent worth $8,043,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Acrospire Investment Management LLC increased its holdings in Catalent by 72.2% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares during the period. Quantbot Technologies LP increased its holdings in Catalent by 110.7% during the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares during the period. Fortaleza Asset Management Inc. bought a new stake in Catalent during the 3rd quarter worth approximately $164,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Catalent by 12.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares during the period. Finally, Advisor Group Inc. increased its holdings in Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the period. 99.37% of the stock is currently owned by institutional investors.
In other news, insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by corporate insiders.
Catalent Inc (CTLT) opened at $42.40 on Friday. The company has a market cap of $5,630.00, a price-to-earnings ratio of 49.30, a PEG ratio of 2.68 and a beta of 1.41. Catalent Inc has a twelve month low of $25.51 and a twelve month high of $43.39. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.16 EPS. equities research analysts expect that Catalent Inc will post 1.46 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “California State Teachers Retirement System Has $8.04 Million Holdings in Catalent Inc (NYSE:CTLT)” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2018/01/12/catalent-inc-ctlt-holdings-cut-by-california-state-teachers-retirement-system-4.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.